Statins: lower lipids and better bones?

被引:0
作者
M.J. Rogers
机构
[1] Bone Research Group,
[2] Dept of Medicine & Therapeutics,undefined
[3] University of Aberdeen Medical School,undefined
来源
Nature Medicine | 2000年 / 6卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Although statins are widely used as cholesterol-lowering drugs, a recent study suggests that these compounds have anabolic effects on bone and could be developed into new treatments for common metabolic bone diseases such as osteoporosis
引用
收藏
页码:21 / 23
页数:2
相关论文
共 10 条
[1]  
Mundy G(1999)Stimulation of bone formation Science 286 1946- 1949
[2]  
Alberts AW(1980) and in rodents by statins Proc. Natl. Acad. Sci. USA 77 3957-3961
[3]  
Hamelin BA(1998)Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent Trends Pharmacol. Sci. 19 26- 37
[4]  
Turgeon J(1996)Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors Ann. Rev. Biochem. 65 241-269
[5]  
Zhang FL(1998)Protein prenylation: molecular mechanisms and functional consequences J. Bone Miner. Res. 13 58 -589
[6]  
Casey PJ(1999)J. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras Proc. Natl. Acad. Sci. USA 96 133-138
[7]  
Luckman SP(1999)Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption and kinase activation Biochem. Biophys. Res. Commun. 264 108-111
[8]  
Fisher JE(1999)Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates J. Clin. Invest. 104 1363 -1374
[9]  
van Beek E(undefined)Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin undefined undefined undefined-undefined
[10]  
Plotkin LI(undefined)undefined undefined undefined undefined-undefined